These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1970550)

  • 1. Characteristics of patients selected for treatment on a schizophrenia research unit.
    Schreiber JL; Breier A; Pickar D
    Hosp Community Psychiatry; 1990 Apr; 41(4):441-3. PubMed ID: 1970550
    [No Abstract]   [Full Text] [Related]  

  • 2. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
    Kopala LC; Fredrikson D; Good KP; Honer WG
    Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
    [No Abstract]   [Full Text] [Related]  

  • 3. Schizophrenia, violence, clozapine and risperidone: a review. The Special Hospitals Treatment Resistant Schizophrenia Research Group.
    Br J Psychiatry Suppl; 1996 Dec; (31):21-30. PubMed ID: 8968652
    [No Abstract]   [Full Text] [Related]  

  • 4. A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trials.
    Schennach-Wolff R; Möller HJ; Jäger M; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Riedel M
    Pharmacopsychiatry; 2010 Nov; 43(7):245-51. PubMed ID: 20927697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do negative symptoms respond to pharmacological treatment?
    Kane JM; Mayerhoff D
    Br J Psychiatry Suppl; 1989 Nov; (7):115-8. PubMed ID: 2575914
    [No Abstract]   [Full Text] [Related]  

  • 6. Factors which can make patients difficult to treat.
    Kane JM
    Br J Psychiatry Suppl; 1996 Dec; (31):10-4. PubMed ID: 8968650
    [No Abstract]   [Full Text] [Related]  

  • 7. Duration of a clozapine trial in neuroleptic-resistant schizophrenia.
    Meltzer HY
    Arch Gen Psychiatry; 1989 Jul; 46(7):672. PubMed ID: 2567591
    [No Abstract]   [Full Text] [Related]  

  • 8. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 9. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation.
    Leucht S; Davis JM; Engel RR; Kissling W; Kane JM
    Acta Psychiatr Scand Suppl; 2009; (438):7-14. PubMed ID: 19132961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical antipsychotic medications and the treatment of schizophrenia.
    Lewis DA
    Am J Psychiatry; 2002 Feb; 159(2):177-9. PubMed ID: 11823256
    [No Abstract]   [Full Text] [Related]  

  • 11. Nemonapride for the treatment of schizophrenia.
    Satoh K; Someya T; Shibasaki M
    Am J Psychiatry; 1997 Feb; 154(2):292. PubMed ID: 9016292
    [No Abstract]   [Full Text] [Related]  

  • 12. Apomorphine's antipsychotic activity.
    Schaffer MH; Davis JM; Tamminga CA
    Arch Gen Psychiatry; 1985 Sep; 42(9):927-8. PubMed ID: 2864035
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients.
    van Berckel BN; Hijman R; van der Linden JA; Westenberg HG; van Ree JM; Kahn RS
    Biol Psychiatry; 1996 Dec; 40(12):1298-300. PubMed ID: 8959296
    [No Abstract]   [Full Text] [Related]  

  • 14. Antipsychotic efficacy of fluperlapine. An open multicenter trial.
    Woggon B; Angst J; Bartels M; Heinrich K; Hippius H; Koukkou M; Krebs E; Küfferle B; Müller-Oerlinghausen B; Pöldinger W
    Neuropsychobiology; 1984; 11(2):116-20. PubMed ID: 6148712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific indications for different classes of phenothiazines.
    Hollister LE; Overall JE; Kimbell I; Pokorny A
    Arch Gen Psychiatry; 1974 Jan; 30(1):94-9. PubMed ID: 4148660
    [No Abstract]   [Full Text] [Related]  

  • 16. Maintenance therapy and the natural course of schizophrenia.
    Davis JM
    J Clin Psychiatry; 1985 Nov; 46(11 Pt 2):18-21. PubMed ID: 2865252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to Shen J, Kobak K, Zhao Y, et al. Use of remote centralized raters via live 2-way video ina multicenter clinical trial for schizophrenia. (J Clin Psychopharmacol. 2008;28:691-693).
    Grunze HC; Höschl C; Montgomery SA; Sartorius N; Vieta E
    J Clin Psychopharmacol; 2009 Aug; 29(4):409; author reply 409-10. PubMed ID: 19593194
    [No Abstract]   [Full Text] [Related]  

  • 18. Age of illness onset and schizophrenic symptomatology during an inpatient washout period.
    Sharma RP; Dowd SM; Davis JM; Janicak PG
    Schizophr Res; 1996 Jul; 20(3):295-300. PubMed ID: 8827856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing symptom response among antipsychotic medications in CATIE.
    Levine SZ; Rabinowitz J; Ascher-Svanum H; Faries DE; Lawson AH
    J Clin Psychopharmacol; 2013 Feb; 33(1):123-6. PubMed ID: 23288232
    [No Abstract]   [Full Text] [Related]  

  • 20. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.